Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight

Rhea-AI Summary

Onco-Innovations (OTCQB:ONNVF) provided a shareholder update outlining 2026 priorities, emphasizing a U.S. growth strategy and clinical translation.

Key 2025 milestones cited include the acquisition of Inka Health AI (Feb 2025), moving its stock listing to the Cboe Canada Market, partnerships with Dalton Pharma (May 2025), collaboration with the University of Alberta and Cross Cancer Institute (June 2025), an agreement with Nucro-Technics (July 2025), and a start-up agreement with Avance Clinical. The company says it is preparing for a Phase 1 clinical trial in 2026 and plans to pursue a U.S. stock exchange cross-listing in 2026 to broaden investor access and R&D engagement.

Positive

• Acquisition of Inka Health AI in Feb 2025
• Moved listing to the Cboe Canada Market
• Partnership with Dalton Pharma (May 2025)
• Collaboration with University of Alberta and Cross Cancer Institute (June 2025)
• Agreement with Nucro-Technics (July 2025)
• Phase 1 clinical trial planned for 2026

Negative

• None.

Focus on U.S. Strategy

VANCOUVER, BC / ACCESS Newswire / October 31, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide a corporate update outlining its strategic objectives for the upcoming year. The update follows Onco-Innovations' CEO Thomas O'Shaughnessy's recent appearance on Cboe Canada's Investor Spotlight (October 22, 2025), where he discussed Onco's mission to enhance cancer treatment technologies through innovation, AI-driven research, and strategic growth initiatives.

Over the past several months, Onco has achieved a series of milestones that have strengthened its scientific and operational foundation, including: acquiring Inka Health AI in February 2025, moving its stock listing to the Cboe Canada Market, partnering with Dalton Pharma Services in May 2025, entering into continued collaboration with the University of Alberta and the Cross Cancer Institute in June 2025, signing an agreement with Nucro-Technics in July 2025 and entering into a start-up agreement with Avance Clinical Pty Ltd, all furthering Onco's research and development efforts.

Building on the progress achieved throughout 2025, Onco is now focused on advancing its programs toward clinical evaluation and strengthening its position in the capital markets. The Company continues to lay the groundwork for a Phase 1 clinical trial in 2026, which would mark a transition from preclinical research and testing to clinical translation.

In the Cboe Spotlight interview, Mr. O'Shaughnessy reflected upon the Company's intention to pursue a U.S. strategy that focuses on enhancing the Company's U.S. presence, including through the pursuit of a U.S. stock exchange cross-listing in 2026. The Company believes that a cross-listing could enhance shareholder value by expanding access to a wider base of potential institutional and retail investors. Additionally, the greater exposure to U.S. capital markets generally would be expected to strengthen engagement with the North American research and development community, supporting Onco's long-term growth trajectory.

"The groundwork we have laid over the past several months has positioned us to move decisively into clinical development. We are now entering an exciting phase where our focus evolves from preclinical success to preparing for clinical validation. Our near-term priorities include completing the necessary steps for our first-in-human trial and advancing our U.S. strategy, both of which will be key drivers of our next stage of growth," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's future plans in relation to, among other things, further research and development, plans to conduct phase 1 and in-human studies and the intention to pursue a U.S. stock exchange cross-listing, as well as the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

What clinical milestone did Onco-Innovations (ONNVF) announce for 2026?

Onco-Innovations is preparing to initiate a Phase 1 clinical trial in 2026 transitioning programs from preclinical to clinical evaluation.

When did Onco-Innovations acquire Inka Health AI and how does that affect ONNVF?

The company acquired Inka Health AI in February 2025, which the company says strengthens its AI-driven research capabilities.

What U.S. market action is Onco-Innovations (ONNVF) planning in 2026?

Management stated an intention to pursue a U.S. stock exchange cross-listing in 2026 to expand investor access and engagement.

Which research and service partners did Onco-Innovations announce in 2025 for ONNVF programs?

Partners announced include Dalton Pharma (May 2025), University of Alberta and Cross Cancer Institute (June 2025), Nucro-Technics (July 2025), and Avance Clinical.

Does Onco-Innovations (ONNVF) have a current Canadian listing?

Yes, the company moved its stock listing to the Cboe Canada Market in 2025.

How does Onco-Innovations describe the purpose of a U.S. cross-listing for ONNVF?

The company said a U.S. cross-listing could expand access to institutional and retail investors and strengthen engagement with North American R&D communities.